الفهرس 
Study the Possible Effects of Saroglitazar and Infliximab on Experimentally Induced Nonalcoholic Steatohepatitis in Rats
Abstract EnglishOnly 14 pages are availabe for public view
 |  | from | 166 |  |  |
| | | from | 166 | | |
Abstract
The most epidemic liver disorder nonalcoholic steatohepatitis (NASH) is characterized by hepatic steatosis and inflammation with hepatocellular damage. Over the next decades, it is predictable to be the most common indication cause for liver transplantation. The absence of an approved therapeutic agent for NASH is a major motivation for research into novel therapeutic strategies. Although the preliminary clinical trials proved that saroglitazar (SAR), with its dual PPAR-Ü/Þ agonist activity is a new candidate for NASH treatment. The efficacy and safety of SAR in the treatment of NASH is still under investigation. Furthermore, investigating Infliximab (INF) in NASH treatment showed promising effects as an anti TNF- Ü monoclonal antibody in recent studies on NASH. Here, we aimed to investigate the effect of SAR and INF on NASH induced in rats by the administration of high {u2013}fat emulsion(HFE) and small doses of lipopolysaccharides (LPS) for 5 weeks. Rats were divided into four groups: negative control group (saline and standard rodent chow), model group (HFE(10 ml/kg/day, oral gavage)+LPS(0.5 mg/kg/week, i.p)), SAR-treated group (HFE(10 ml/kg/day, oral gavage)+LPS(0.5 mg/kg/week, i.p.) + SAR(4 mg/kg/day, oral gavage), and INF-treated group (HFE(10 ml/kg/day, oral gavage)+LPS(0.5 mg/kg/week, i.p) + INF(7 mg/kg/day, i.p) starting treatments at week 3